Skip to content

Intravenous Versus Oral Administration of Prednisolone in Exacerbations of Chronic Obstructive Pulmonary Disease (COPD)

A Comparison of Intravenous Versus Oral Administration of Prednisolone in the Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00311961
Enrollment
256
Registered
2006-04-07
Start date
2001-06-30
Completion date
2003-08-31
Last updated
2009-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

COPD, Exacerbations, Corticosteroids, Oral, Intravenous, Chronic Obstructive Pulmonary Disease (COPD)

Brief summary

Treatment with systemic corticosteroids for acute exacerbations of COPD results in the improvement of clinical outcomes. The optimal route of administration has not been rigorously studied in COPD. Upon hospitalization, corticosteroids are administered intravenously in many hospitals. Oral administration is more convenient, though, because there is no need for intravenous access, less personnel is required for starting and monitoring therapy, and material costs are smaller. The investigators hypothesized that oral administration is not inferior to intravenous administration of prednisolone in the treatment of patients hospitalized for an acute exacerbation of COPD.

Interventions

Sponsors

Isala
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum

Inclusion criteria

* Exacerbation of COPD (at least Global Initiative for Chronic Obstructive Lung Disease \[GOLD\] severity stage II) * Smoking history of \> 10 pack years

Exclusion criteria

* Signs of severe exacerbation (arterial pH \< 7.26 or pCO2 \> 9.3 kPa) * History of asthma * Significant or unstable co-morbidity * Participated in another study 4 weeks before admission * Previously randomized to this study * Findings on chest radiography other than those fitting with signs of COPD * Known hypersensitivity to prednisolone * Non-compliant

Design outcomes

Primary

MeasureTime frame
and the necessity to intensify pharmacologic treatment
Treatment failure defined as: death from any cause
admission to the intensive care unit
readmission to the hospital because of COPD

Secondary

MeasureTime frame
Changes in forced expiratory volume in 1 second (FEV1)
St. George's Respiratory Questionnaire (SGRQ) scores
Clinical COPD Questionnaire (CCQ) scores
and length of hospital stay

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026